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Background: Chronic Total Occlusion (CTO) recanaliza-
tion is a complex and technically challenging procedure. The
J-CTO score has been proposed to stratify case complexity
and procedural success rates. However, the score has never
been tested outside the setting of the original study. More-
over, its predictive value when using a hybrid antegrade or
retrograde approach is unknown. We investigated the per-
formance of the J-CTO score for predicting procedure
complexity and success in an independent contemporary
cohort.
Methods and results: A total of 209 consecutive patients
who underwent CTO recanalization by a high-volume oper-
ator were included. Clinical and angiographic data were
prospectively collected. The J-CTO score was applied for
each patient, and discrimination and calibration were eval-
uated in the whole cohort, and according to the approach
(antegrade 47% and retrograde 53%). Clinical and angio-
graphic differences were noted between the original and
studied cohort. The mean J-CTO score was 2.18 ± 1.26, and
successful guidewire crossing within 30 min and final
angiographic success were 44.5% and 90.4%, respectively.
The J-CTO score demonstrated good discrimination (c sta-
tistic, >0.70) and calibration (HosmereLemeshow p > 0.1) in
the whole cohort and for antegrade and retrograde ap-
proaches. However, the final success rate was not associated
with the J-CTO score.
Conclusions: In this independent cohort, the J-CTO score
showed good discriminatory and calibration capacity for
guidewire CTO crossing within 30 min but it does not for final
success rate. The J-CTO score helps to predict complexity of
CTO recanalization, and the simplicity of the score supports
the widespread use as a clinical tool.1. Perspective
The multicenter Japanese CTO Registry investigators had
originally developed the J-CTO score, which was used to
determine the difficulty in crossing a CTO within 30 min and
overall success rate.1 It utilized 5 independent predictors: 1)calcification 2) bend >45 in the CTO segment 3) blunt prox-
imal cap 4) length of occluded segment >20 mm 5) previously
failed attempt. 1 point was given to each variable. The CTO
case complexity was stratified as easy (J-CTO score ¼ 0), in-
termediate (score ¼ 1), difficult (score ¼ 2) and very difficult
(scores ¼ 3e5). However, this score was never tested outside
the setting of the original study and its validity was also not
tested in a non-Japanese population.
It is in this context that the present study holds signifi-
cance. It has validated the J-CTO score in an independent
and unselected CTO PCI cohort. It has reinforced the find-
ings of the original Japanese study in a non-Japanese pop-
ulation. However, although it predicted guidewire crossing
within 30 min, it failed to predict overall success rate. In
contrast, in another series2 with a longer inclusion period,
the J-CTO score was also predictive of successful
recanalization.
A careful evaluation of the lesion complexity is essential
before attempting CTO recanalization both for the high-
volume and low-volume CTO operators. The present study
has established the J-CTO score as a useful tool to stratify CTO
PCI complexity in all populations. It can also predict procedure
time, contrast load and radiation exposure, all of which are of
paramount importance in planning a CTO PCI.
In my opinion, the J-CTO score is a relatively simple and
useful score to predict the time to guidewire crossing and also
overall success rates and total procedure time in CTO PCI. It
can clearly assist interventional cardiologists in decision-
making process. CTO with low scores could be attempted
using simple antegrade techniques by low-volume CTO op-
erators while those with higher scores are preferably to be
referred to high-volume CTO operators proficient in both
antegrade and retrograde approach. In dedicated CTO Cath
labs, it can be useful to plan the schedule, to optimize case
number and to reduce failure rates of CTO PCI. Widespread
application of this novel scoring system is the need of the
hour.r e f e r e n c e s
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Objectives: This study sought to evaluate the safety and
efficacy of rosuvastatin in preventing contrast-induced acute
kidney injury (CI-AKI) in patients with diabetes mellitus (DM)
and chronic kidney disease (CKD).
Background: CI-AKI is an important complication after
contrast medium injection. While small studies have shown
positive results with statin therapy, the role of statin therapy
in prevention of CI-AKI remains unknown.
Methods: We randomized 2998 patients with type 2 DM
and concomitant CKD who were undergoing coronary/pe-
ripheral arterial angiography with or without percutaneous
intervention to receive rosuvastatin, 10 mg/day (n ¼ 1498), for
5 days (2 days before, and 3 days after procedure) or standard-
of-care (n ¼ 1500). Patients' renal function was assessed at
baseline, 48 h, and 72 h after exposure to contrast medium.
The primary endpoint of the studywas the development of CI-
AKI, which was defined as an increase in serum creatinine
concentration 0.5 mg/dl (44.2 mmol/l) or 0.25% above base-
line at 72 h after exposure to contrast medium.
Results: Patients randomized to the rosuvastatin group had
a significantly lower incidence of CI-AKI than controls (2.3%
vs.3.9%, respectively; p ¼ 0.01). During 30 days' follow-up, the
rate of worsening heart failure was significantly lower in the
patients treated with rosuvastatin than that in the control
group (2.6% vs. 4.3%, respectively; p ¼ 0.02).
Conclusions: Rosuvastatin significantly reduced the risk of
CI-AKI in patients with DM and CKD undergoing arterial
contrast medium injection.1. Perspective
CI-AKI risk increases dramatically in patients with DMor CKD.
Besides these, other risk factors for CI-AKI are: 1) presentationas ACS 2) advanced NYHA Class 3) anaemia and 4) decreased
eGFR. Because these risk factors can be easily identified, pro-
phylactic measures for the prevention of CI-AKI should be
considered in these patients.
Present day strategies to prevent CI-AKI include: 1) intra-
venous hydration with saline 2) reduced use of contrast and
preferably an iso-osmolar agent like iodixanol and 3) N-acetyl
cysteine (NAC).
The present study is the first of its kind, which has evalu-
ated short-term (5 days) low dose rosuvastatin (10 mg/day)
started 2 days prior to angiography or PCI in patients with DM
and stage 2 or 3 CKD. The incidence of CI-AKI was significantly
lower in patients receiving rosuvastatin in comparison to
those receiving standard treatment strategies. 62.5 patients
would need to be treated to prevent one case of CI-AKI.
The strength of the present study is its large sample size
(3000 patients), all diabetics and with mild CKD. Rosuvastatin
prevents CI-AKI even in patients with normal lipid levels. The
most beneficial effect was seen in patients with stage 2 (mild
CKD).
Statins are known to exert pleiotropic effects and have
anti-inflammatory action via reduced hsCRP levels. The pre-
ventive effects of rosuvastatin on CI-AKI can be because of 1)
anti-inflammatory action 2) prevention of direct contrast
toxicity like apoptosis of renal cells.
In my opinion, identification of patients at risk of CI-AKI
and institution of measures like intravenous hydration and
use of low volume of contrast is of paramount importance.
Patients undergoing angiography and PCI anyway receive
statins. The present study only re-emphasizes this point. The
extra knowledge this study has added is that even in patients
with mild CKD, emphasis should be given to prevent CI-AKI
and low dose short duration statins are a newer addition to
the present day preventive measures for CI-AKI.
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